- Home
- GS vs ABBV Comparison
GS vs ABBV Comparison
Compare GS & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GS | ABBV |
|---|---|---|
| Founded | 1869 | 2012 |
| Country | United States | United States |
| Employees | 47000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.5B | 358.5B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | GS | ABBV |
|---|---|---|
| Price | $1,081.67 | $233.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 18 |
| Target Price | ★ $901.19 | $253.71 |
| AVG Volume (30 Days) | 2.2M | ★ 3.9M |
| Earning Date | 04-13-2026 | 04-29-2026 |
| Dividend Yield | 1.99% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $10.40 | $11.87 |
| Revenue Next Year | $4.84 | $8.12 |
| P/E Ratio | ★ $18.19 | $601.87 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $691.30 | $181.75 |
| 52 Week High | $1,125.00 | $244.81 |
Technical Indicators
Market Signals| Indicator | GS | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 63.96 |
| Support Level | $877.99 | $220.11 |
| Resistance Level | $1,098.36 | $237.81 |
| Average True Range (ATR) | 32.62 | 5.27 |
| MACD | 0.42 | 0.74 |
| Stochastic Oscillator | 68.14 | 83.99 |
Price Performance
Historical ComparisonAbout GS Goldman Sachs Group Inc. (The)
Goldman Sachs is a storied financial institution, founded in 1869 and best known for its role as a leading global investment bank. The firm has a sprawling reach across global financial centers and has been the leading provider of global merger and acquisition advisory services, by revenue, for the past 20 years. Since the global financial crisis, Goldman has expanded its offerings into more stable fee-based businesses like asset and wealth management, which comprised roughly 30% of post-provision revenue at the end of 2025. The firm generates revenue from investment banking, global market making and trading, lending, asset management, wealth management, and a small and declining portfolio of consumer credit card loans.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.